fenofibrate has been researched along with bexarotene in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barnouin, R; Calleja, C; Cantiello, M; Concordet, D; Gauthier, B; Lasserre, F; Martin, PG; Pineau, T; Roulet, A; Van Es, A | 1 |
| Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W | 1 |
| Ardizzoni, A; Di Nuzzo, S; Musolino, A; Panebianco, M; Santini, M; Zendri, E | 1 |
| Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS | 1 |
| Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O | 1 |
1 review(s) available for fenofibrate and bexarotene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for fenofibrate and bexarotene
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks.
Topics: Animals; Apolipoproteins; Bexarotene; Blotting, Northern; Cell Nucleus; Cluster Analysis; Dimerization; Fenofibrate; Gene Expression Regulation; Genotype; Hypolipidemic Agents; Kidney; Liver; Lymphoma, T-Cell, Cutaneous; Male; Mice; Mice, Inbred C57BL; Models, Genetic; Models, Statistical; Oligonucleotide Array Sequence Analysis; PPAR alpha; Principal Component Analysis; Retinoid X Receptor alpha; Retinoids; RNA; Signal Transduction; Tetrahydronaphthalenes; Time Factors; Tissue Distribution; Transcription, Genetic; Triglycerides; Vitamin D | 2005 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fever; Granuloma; Humans; Hydroxamic Acids; Hypolipidemic Agents; Middle Aged; Mycosis Fungoides; Necrosis; Remission Induction; Skin; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2008 |
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Topics: Adult; Aged; Bexarotene; Contraindications; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, HDL; Clinical Protocols; Drug Administration Schedule; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver Function Tests; Lymphoma, T-Cell, Cutaneous; Musculoskeletal Pain; Pancreatitis; Pregnancy; Pregnancy Complications; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin; Thyroxine | 2013 |
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Chemotherapy, Adjuvant; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipid Metabolism; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Tetrahydronaphthalenes | 2017 |